ORIC Pharmaceuticals Completes Dose Exploration Part Of ORIC-944 Phase 1b Trial

Benzinga · 11/13/2025 21:25

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided clinical and operational updates for the quarter ended September 30, 2025.

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety

Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development

Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114)

Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiation of registrational trials for both programs in 2026